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Diabetic kidney disease is a major cause of renal failure that urgently necessitates a break-
through in disease management. Here we show using untargeted metabolomics that levels of
phenyl sulfate, a gut microbiota-derived metabolite, increase with the progression of diabetes
in rats overexpressing human uremic toxin transporter SLCO4C1 in the kidney, and are
decreased in rats with limited proteinuria. In experimental models of diabetes, phenyl sulfate
administration induces albuminuria and podocyte damage. In a diabetic patient cohort, phenyl
sulfate levels significantly correlate with basal and predicted 2-year progression of albumi-
nuria in patients with microalbuminuria. Inhibition of tyrosine phenol-lyase, a bacterial
enzyme responsible for the synthesis of phenol from dietary tyrosine before it is metabolized
into phenyl sulfate in the liver, reduces albuminuria in diabetic mice. Together, our results
suggest that phenyl sulfate contributes to albuminuria and could be used as a disease marker
and future therapeutic target in diabetic kidney disease.
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D iabetic kidney disease (DKD) occurs in approximately20–30% of all diabetic subjects and represents a majorcause of end-stage renal disease (ESRD), cardiovascular
events and death1,2. It is difficult to identify type 2 diabetes
patients who are at risk of developing progressive DKD based
only on measurements of glomerular filtration rate (GFR) and
albuminuria3. Specific biomarkers are needed for identifying
individuals during the early stages of diabetes who are at high risk
of complications2.
The major function of the kidney is the filtration or transport
of various circulating endogenous and exogenous compounds
into the urine4. Type 2 diabetes causes significant changes in an
array of plasma metabolites, even in the early stages5. In the
kidney, the organic anion transporting polypeptide (OATP)
transporter family contributes to the transport of various organic
anions and cations into the urine. In rodent kidney, several oatp
gene products are present at the proximal tubules, whereas
SLCO4C1 is the only OATP in human kidney4. The diversity
among the oatp family members makes it difficult to extrapolate
from experimental studies on rodents to humans. To overcome
this issue, we generated transgenic rats overexpressing human
SLCO4C1 in the proximal tubule6. These rats are an excellent
model for evaluating the human kidney-specific elimination for
metabolites and uremic toxins. We previously clarified that the
excretion of uremic toxins in the SLCO4C1 transgenic rat model
reduced hypertension, cardiomegaly, and inflammation in the
setting of renal failure6.
Here, using this model, we characterize metabolites that are
increased in diabetic wild-type rats (WT-DM), but reduced in
diabetic SLCO4C1 transgenic rats (Tg-DM). We find that levels
of phenyl sulfate (PS), a gut microbiota-derived metabolite, sig-
nificantly correlate with basal and predicted 2-year progression of
albuminuria in patients with microalbuminuria. Inhibition of PS
production reduces albuminuria in diabetic mice. Together, our
results suggest that PS is not only an early diagnosis marker, but
also a modifiable cause and therefore a target for the treatment of
DKD.
Results
Reduction of PS reduced proteinuria in a rat diabetes model.
To identify metabolites linked to diabetic conditions, streptozo-
tocin (STZ)-induced diabetes was induced in SLCO4C1-Tg rats
on day 0. On day 7, bloods were collected and rats with blood
glucose levels greater than 300 mg/dl were selected for further
analysis. Dietary intake and body weights were similar in WT-
DM and SLCO4C1-Tg DM rats (Fig. 1). Blood glucose levels
increased following STZ (~500mg/dl) and, during the experi-
mental period, blood glucose levels were similar in both groups,
except on day 90. The WT-DM and Tg-DM groups showed no
differences in renal function. However, proteinuria in the Tg-DM
group was significantly lower than in the WT-DM group on days
7, 30, and 63, but showed a non-significant trend on days 90 and
119 (Fig. 1a). Histological analysis showed that glomerulomegaly
was present in the WT-DM group, but reduced in the Tg-DM
group (Fig. 1b). No significant change was observed in the pre-
served tubular and fibrotic areas between WT-DM and Tg-DM
rats (Supplementary Fig. 1). These data suggest that over-
expression of SLCO4C1 in diabetic kidney decreases proteinuria
without major histological changes, except in glomeruli at the
light microscopic level.
Identification of PS as a pathogen-derived metabolite in DKD.
Since SLCO4C1 is a transporter that eliminates metabolites into
urine, we concluded that excretion of a SLCO4C1-specific sub-
strate into urine caused a reduction in proteinuria. Initially, we
performed untargeted metabolome profiling to screen for major
molecular differences using ultra high-performance liquid chro-
matography (UHPLC) coupled to quadrupole time-of-flight mass
spectrometry (UHPLC-QTOF/MS). Over 4173 features were
detected from the 5 groups: WT day 7 (WT-d7), WT day 63
(WT-d63), WT day 119 (WT-d119), SLCO4C1-Tg day 63 (Tg-
d63), and SLCO4C1-Tg day 119 (Tg-d119). Totally, 17.6% (or
827) of the features with a coefficient of variation (CV) ≥30%
were excluded and the remaining 3886 features were selected
(Supplementary Data 1). Principle component analysis (PCA)
was conducted on all groups (Supplementary Fig. 2a), all WT
groups (days 7, 63, and 119, Supplementary Fig. 2b) and all TG
groups (days 63 and 119, Supplementary Fig. 2c). Although some
broad-based overlapping clustering can be observed, these ana-
lyses showed no clear distinction among the groups. This sug-
gested that the largest source of variation is within each group
and not among the groups.
To maximize and analyze differences among the five groups,
partial least square-discriminant analysis (PLS-DA) was also
performed. Figure 1c shows separation of the five groups
analyzed. To evaluate the effect of STZ and highlight the most
robust markers of interest, we used orthogonal PLS-DA (OPLS-
DA). We compared the plasma metabolomes between WT-d7
and WT-d119 rats, a time interval during which diabetic changes
progressed (Fig. 1d). The OPLS-DA scores plot of WT-d7 and
WT-d119 mice (Supplementary Fig. 2d) showed good fit and high
predictability of the model with values for R2Y (which assesses the
extent to which the data fit the model) and the quality assessment
metric Q2 of 0.994 and 0.956, respectively. From the S-plot of the
OPLS-DA7, 94 features that were significantly higher in WT-d119
also had a correlation value (p(corr)[1]) >0.85 (up to 1.0). These
features were further filtered down to components with a low %
CV (<15%) (Supplementary Table 1).
We next looked for analytes with high variable importance in
projection (VIP) scores, which assess the relative contribution to
the OPLS-DA model. These analyses identified one metabolite
(m/z 172.97, red circle and arrow) that showed a distinctly strong
contribution (high p[1]) relative to the other features, with a fold
change of 1.9, a distinct VIP score of 5.9 relative to the other
components of VIP score <1.5 (Fig. 1d, Supplementary Table 1).
Further investigation revealed that it increased with diabetes
progression. This increase was significantly reduced in SLCO4C1-
Tg rats when compared to WT rats on days 63 and 119. This
metabolite also showed a distinctly strong contribution relative to
the other components in the S-plot of WT-d63 vs. Tg-d63
(Fig. 1e, red arrow) and the S-plot of WT-d119 vs. Tg-d119
(Fig. 1f). In summary, this feature was the only one to fulfill the
selection criteria of increasing with the progression of diabetes
and being reduced in Tg rats, and led to its selection for further
investigation. The change in intensity of m/z 172.97 is shown in
Fig. 1g. The fold changes and associated p values for WT-d63 vs.
Tg-d63 and for WT-d119 vs. Tg-d119 are listed in Supplementary
Table 1.
To identify the feature, the elemental composition was
analyzed and predicted to be C6H5O4S ([M-H]−), with a
theoretical value of m/z 172.97. A search of the Chemspider
database using the predicted elemental composition C6H5O4S
([M-H]−) revealed the following candidates: 2-hydroxybenzene-
sulfonate, 3-hydroxybenzenesulfonate, 4-hydroxybenzenesulfo-
nate, and PS. We tried to identify these features by matching
fragments of the MS/MS spectra obtained from rat plasma. The
product ions found in the corresponding extracted MSE high-
energy spectrum at m/z 79.9, m/z 93.0, m/z 109.0, and m/z 121.0
were hypothesized to be [M-C6H5O-H]−, [M-SO3-H]−, [M-SO2-
H]−, and [M-C4H4-H]−, respectively (Fig. 1h). Finally, the
identity was confirmed using a synthesized chemical standard of
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PS (Fig. 1i), which provided a similar fragmentation pattern and
retention time. The plasma PS levels measured precisely by liquid
chromatography (LC)/MS/MS8 in WT-DM rats on days 63 and
119 were 4.47 ± 0.43 and 6.48 ± 0.71 μM, respectively, and these
levels were decreased in Tg-DM rats (Supplementary Fig. 3). To
confirm whether PS is a substrate of SLCO4C1, an uptake study
was performed using SLCO4C1-expressing MDCK (SLCO4C1/
MDCKII) cells9. The uptake of PS into cells was increased in
SLCO4C1/MDCKII cells, verifying PS as a substrate for the
SLCO4C1 transporter (Fig. 1j). We also examined PS uptake
using human proximal tubular HK-2 cells. The uptake of PS by
HK-2 cells was inhibited by the SLCO4C1 inhibitor ritonavir
h i
m/z
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(Supplementary Fig. 4). These data demonstrated that PS
increased with the progression of diabetes. Urinary protein and
PS accumulated in diabetic rats were reduced by the over-
expression of SLCO4C1 in the kidney.
PS-induced albuminuria by podocyte damage in diabetic
models. We used several models to determine whether PS plays a
pathogenic role in the progression of albuminuria and diabetic
renal damage. The basal PS level in db/db mice was 3.06 ±
2.63 μM (Fig. 2a, n= 5). To accelerate phenotypic changes, we
administered PS orally to two types of diabetes models. Oral
administration of PS to db/db mice (50 mg/kg) resulted in a rapid
rise in plasma PS to 64.53 ± 5.87 μM in 1 h, which then rapidly
decreased (n= 3, Supplementary Fig. 5). After oral administra-
tion of PS to db/db mice for 6 weeks, the plasma level was sig-
nificantly increased by 5-fold (27.3 ± 9.17 μM, Fig. 2a). There was
no change in the biological data between control db/db mice and
PS-treated db/db mice (Supplementary Table 2).
Since PS is usually detected in renal failure and recognized as a
gut-derived uremic toxin10, we measured the plasma level of
other gut microbiota-derived uremic toxins (p-cresyl sulfate
(PCS), indoxyl sulfate (IS), and trimethylamine N-oxide
(TMAO), Fig. 2a). We found no significant differences in PCS,
IS, and TMAO concentrations following PS administration.
Albuminuria was increased in db/db mice supplemented with PS
(Fig. 2b).
Because podocyte injury causes albuminuria11, we focused on
the effect of PS on podocytes. Histological examination by light
microscopy revealed mesangial expansion, but not significant
(Fig. 2c). However, electron microscopy revealed increased the
foot processes effacement (Fig. 2c, white arrows) and the
glomerular basement membrane thickening (GBM) (Fig. 2c,
yellow arrow heads) in PS-treated db/db mice. These data suggest
that PS elicits podocyte damage in diabetic mice. In addition,
although there was no difference between in the preserved tubular
area and fibrotic area at the light microscopic level (Supplemen-
tary Fig. 6a), the expression levels of representative inflammatory
genes, TNF-α (Tnfa) and MCP-1 (Ccl2), the fibrotic gene TGF-α1
(Tgfb1), fibronectin (Fn1), and collagen I (Col1a1) were increased
in PS-treated db/db kidney (Supplementary Fig. 6b). It was
reported that db/db mice develop renal fibrosis12. Our data
further suggest pro-fibrotic and pro-inflammatory effects of PS in
the DKD model.
To confirm the toxic effect of PS on podocytes, we employed
cell survival analysis using differentiated human urinary
podocyte-like epithelial cells (HUPECs)13. As shown in Fig. 2d,
PS was toxic to differentiated podocytes from 30 μM and
significant cell toxicity was seen at concentrations from 100 μM.
We also measured the effect of PS on glutathione levels, as it was
reported PS decreases glutathione levels, rendering the cells
vulnerable to oxidative stress14. Glutathione levels in differen-
tiated podocytes exposed to PS (30 μM) decreased and significant
at 100 μM (Fig. 2e). This was comparable to reports in CKD
(~62 μM)15 and in our human DKD study (0–68.1 μM, Table 1).
Since podocyte mitochondrial dysfunction was also reported in
the pathogenesis of DKD16, we examined the bioenergetic effect
of PS on cultured podocytes17. By measuring the oxygen
consumption rate (OCR), PS (100 μM to 1mM) exposure to
differentiated podocytes significantly decreased mitochondrial
basal respiration, ATP production, H+ leaking and maximum
respiration capacity, suggesting that PS is toxic to mitochondria
(Fig. 2f and Supplementary Fig. 7). PS also increased non-
mitochondrial respiration, suggesting respiration compensation.
Extracellular acidification rate (ECAR) measuring glycolysis did
not differ between PS-treated and control differentiated podo-
cytes, further suggesting that glycolysis was not compensated
enough.
To confirm the effect of PS in diabetic kidney, we also
administered PS (50 mg/kg) to KKAy mice fed on a high-fat diet
(HFD), another model of DKD18. The plasma PS level was
significantly increased to 6.09 ± 3.18 μM (n= 4) in PS-treated
HFD-KKAy mice compared to non-PS-treated HFD-KKAy mice
(1.48 ± 0.85 μM; Fig. 2g, n= 3)). The clinical data had not
changed (Supplementary Table 3). Oral administration of PS to
HFD-KKAy mice for 6 weeks increased albuminuria (Fig. 2g).
Electron micrographs revealed podocyte effacement (Fig. 2h,
white arrows) and GBM thickening (Fig. 2h, yellow arrow heads)
and damage in the PS-treated HFD-KKAy kidney. Elastica
Masson and F4/80 staining showed some perivascular fibrotic
area in the PS-treated group (Fig. 2h, black arrow heads). These
results further suggest that the manifested podocyte damage and
perivascular inflammation were elicited by PS, which contributed
to albuminuria in HFD-KKAy mice.
We further examined diabetic mice lacking endothelial nitric
oxide synthase (eNOS) by introducing the Akita mutation in the
insulin2 (Ins2) gene19. This is a model of severe diabetes that
recapitulates human DKD with mesangial expansion, mesangio-
lysis, glomerulosclerosis, and GBM thickening19. In this model,
blood glucose level of eNOS-KO mice was 150 ± 15 mg/dl and
this level was significantly increased at 460 ± 45 mg/dl at 6 months
(n > 5). The urinary albumin level was also increased in eNOS-
KO-DM mice (413 ± 107 μg/mgCr) compared to that in eNOS-
KO mice (36 ± 4 μg/mgCr)19. The plasma PS level in eNOS-KO-
DM mice was significantly increased (15.4 ± 2.73 μM, n= 5)
compared with control eNOS-KO mice (5.97 ± 0.47 μM, Fig. 2i),
although the renal function in both DM and non-DM mice was
normal. Histological examination revealed that NOS-KO-DM
diabetic mice showed significant changes in glomerulosclerosis
Fig. 1 Diabetic SLCO4C1-Tg rats showed reduced proteinuria. a Body weight, blood glucose, blood urea nitrogen (BUN), and creatinine clearance (Ccr) in
diabetic SLCO4C1-Tg rats (white circles, n= 5) and WT rats (black circles, n= 6). b Representative PAS (left) stained sections of WT and SLCO4C1-Tg rat
glomeruli. Bars= 100 μm. n= 50 in each group. Data are mean ± SEM. *p < 0.05 vs. WT. Student t test. c Variation in the five groups in the PLS-DA scores
plot using the chemical features detected in plasma. Sample conditions are represented by color coded circles: WT-d7 (black), WT-d63 (blue), WT-d119
(cyan), Tg-d63 (red), and Tg-d119 (orange). Groups D7, D63, and D119 are surrounded by black, red, and orange solid rings, respectively. Groups WT-d63,
WT-d119, Tg-d63, and Tg-d119 are surrounded by blue, cyan, red, and orange dotted rings, respectively. d S-plot analyses of orthogonal partial least square-
discriminant analysis (OPLS-DA) of WT rats on days 7 and 119. The selected 94 features (surrounded by a dotted red rectangle) were significantly greater
on day 119 than on day 7. e S-plot analyses of OPLS-DA of WT and Tg rats on day 63. f S-plot analyses of OPLS-DA of WT and Tg rats on day 119. g Changes
in the concentration of the selected feature m/z 172.97 with the progression of diabetes. Wild-type rats (white column, n= 6); SLCO4C1-Tg rats (black
column, n= 5). h Fragment ion mass spectrum of m/z 172.97. The main detected precursor and fragment ion was m/z 172.97. The product ions found in the
corresponding extracted MSE high-energy spectrum atm/z 79.9, m/z 93.0, m/z 109.0, andm/z 121.0 were hypothesized to be [M-C6H5O-H]-, [M-SO3-H]-,
[M-SO2-H]-, and [M-C4H4-H]-, respectively. i Chemical structure of PS. j SLCO4C1-mediated PS uptake by SLCO4C1/MDCKII cells (n= 3). Data are
mean ± SEM. *p < 0.05 vs. control according to Student t test (a, b, g, j). Source data are provided as a Source Data file and untargeted metabolome data are
provided as a Supplementary Data 1
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compared with NOS-KO-control mice (Fig. 2j). These data
further suggested that a higher PS level shows much severer
glomerular lesion.
PS is a predictor for incipient albuminuria in DKD patients.
To confirm the relationship between PS and albuminuria
observed in animal experiments, we recruited 362 diabetes
patients from the U-CARE (urinary biomarker for continuous
and rapid progression of diabetic nephropathy) study20. We
analyzed two parameters: (i) the relationship between the baseline
PS and albuminuria and (ii) the relationship between the baseline
PS concentration and the progression of albuminuria up until 2
years later. We also measured soluble urokinase-type plasmino-


























































































































































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09735-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1835 | https://doi.org/10.1038/s41467-019-09735-4 | www.nature.com/naturecommunications 5
incidence and progression of DKD by modification of podocyte
barrier function21,22.
Participants in the U-CARE study (n= 362) had a mean age of
63.3 years, and 56.9% were male. The mean blood glucose
concentration (BS) was 154.2 ± 56.4 mg/dl and the HbA1c was
7.2 ± 1.1%. The eGFR was 73.8 (17.1–115.4) ml/min/1.73 m2 and
the albumin-to-creatinine ratio (ACR) was 11.0 (1.0–6407.4) mg/
gCr. The serum PS level was 3.3 μM (0–68.1 μM) and suPAR was
460.8 (142–2740.2) pg/ml (Table 1). Supplementary Table 4
shows clinical data for patients with DKD based on the
albuminuria and Fig. 3a shows the PS level.
In the Spearman rank-order test (Supplementary Table 5), the
plasma PS level significantly correlated with ACR (Fig. 3b), eGFR
(Fig. 3c), age, duration, HbA1c, and uric acid (UA), but not
with suPAR (Fig. 3d). We next performed multiple regression
analysis. To evaluate, we built three models: model 1 (crude
model); model 2 (adjusted by known factors: age, gender, BMI,
SBP, HbA1c, log (eGFR))23; and model 3 (full model; adjusted by
model 2 plus other clinical factors in Supplementary Table 4, i.e.,
DBP, ALT, total cholesterol (TC), triglyceride (TG), high-density
lipoprotein (HDL) and UA). Multiple regression analysis revealed
that ACR was the only factor that significantly correlated with PS
among all models (Table 2). Stepwise analysis for progression
using known factors indicated the significance of the same factors.
In addition, vice versa, analysis performed with ACR as an
objective variable revealed that PS significantly correlated with
the ACR among all models as well as stepwise analysis (Table 3).
In this analysis, eGFR, gender, and blood pressure were
also related to the ACR, as reported24, suggesting the validity of
our cohort.
Given the significant relationship between baseline PS and
albuminuria, we examined logistic regression models to identify
factors independently associated with the development of the
2-year ACR (Table 4). The mean follow-up duration was 2.1 ± 0.2
years (median= 2.1 years, interquartile range: 2.0–2.2 years).
Based on model 1, PS and suPAR were the only factors related to
the amount of change in the ACR during the 2 years, suggesting
that PS and suPAR are independent risk factors for the ACR. In
models 2 and 3, PS and suPAR were not significant. However,
receiver operating characteristic (ROC) curve analysis revealed
that the c-statistics value—the areas under the curve ROC (AUC-
ROC) using known factors23 was 0.674 and the combination of
PS increased the c-statistics value to 0.708 (Supplementary
Fig. 8a). A combination of suPAR with known factors did not
increase the c-statistics value from 0.674 to 0.664 (Supplementary
Fig. 8b). However, the combination of PS with known factors, as
well as suPAR, further increased the c-statistics value from 0.664
to 0.702 (Supplementary Fig. 8c).
Based on this, we performed stratified logistic analysis based on
the disease stage. Owing to the insufficient number of macro-
albuminuria patients for analysis, we examined the normoalbu-
minuria and microalbuminuria groups (Supplementary Table 6).
In the normoalbuminuria group, PS was not related to the
amount of change in the ACR during the 2 years in all models
(Supplementary Table 6). On the other hand, in the micro-
albuminuria group, PS was the only factor related to the amount
of change in the 2-year ACR in all three models, with an odds
ratio of 2.02 (CI: 1.04–3.92) in model 2 (Fig. 3e and
Supplementary Table 6). Stepwise model also indicated the
significance of PS. However, suPAR was not related in either
the normoalbuminuria or macroalbuminuria groups. ROC curve
analysis also showed that the c-statistics value using known
factors was 0.713 and the combination of PS increased this to
0.751 (Fig. 3f). A combination of suPAR with known factors also
increased the c-statistics value from 0.713 to 0.725 (Fig. 3g).
Further combination of PS with known factors and suPAR, still
increased the c-statistics value from 0.725 to 0.752 (Fig. 3h).
These data suggested that PS was related to ACR and that the PS
Fig. 2 Pathophysiological features of PS in vitro and in vivo. a Plasma levels of PS, PCS; IS, and TMAO in 11-week-old db/db mice in control (Ctrl; n= 5) or
PS (50mg/kg/day for 6 weeks, n= 6). b Plasma albumin and Cr levels before and after administering PS for 6 weeks to db/db mice. Control (white circles,
n= 5) and PS-treated (black circles, n= 6) groups. c Glomeruli in db/db mouse with or without PS for 6 weeks. Bar, 80 μm (PAS) and 1 μm (EM). d Cell
toxicity analysis (n= 6). e Cellular GSH level (n= 6). f Bioenergetic characterization of cultured human podocytes in terms of oxygen consumption rate
(OCR). n= 4. g PS, albuminuria and Cr levels before and after administering PS for 6 weeks in HFD-KKAy mouse (6 weeks old). For PS, n= 3 (HFD-
control) and n= 4 ((HFD-PS). For Cr and albuminuria, n= 4. Wilcoxon (PS) and Student’s t test (Cr and albuminuria). h Histological images of PAS and
electron microscopic analysis of podocytes from control (Ctrl; top row) and PS-treated (PS; bottom row) groups of HFD-KKAy mice. Scale bar= 200 μm
for PAS and 1 μm for electron microscopy. The effacement of podocytes (white arrows) and GBM thickness (yellow arrow heads) are shown. The
inflammatory area (Elastica Masson) and macrophage infiltration (F4/80 immunostaining) around the vascular area are indicated (black arrow heads).
Scale bar, 80 μm. i PS levels in eNOS knockout mice with or without diabetes (n= 5). j Histological examination stained with PAS of eNOS knockout mice
with or without diabetes. Scale bar, 50 μm. *p < 0.05 vs. control according to Student t (a, b, d, e, I, j) or Tukey’s test (f). Source data are provided as a
Source Data file
Table 1 Baseline and 2-year after characteristics of the U-
CARE study
Baseline After 2 years
PS (μM) 3.3 (0–68.1)
suPAR (pg/mL) 460.8
(142.0–2740.2)
Age (years) 63.3 ± 12.4 65.3 ± 12.4
Gender (M/F) 206/156 206/156
DM type (1/2/others) 40/318/4
Duration (years) 14.6 ± 8.8 16.6 ± 8.8
Time to
measure
(years) 2.08 ± 0.18
BMI (kg/m2) 25.0 ± 4.4
SBP (mmHg) 127.8 ± 15.2 128.6 ± 15.8
DBP (mmHg) 72.4 ± 10.2 72.1 ± 10.6
BS (mg/dL) 154.2 ± 56.4 159.5 ± 60.6





ACR (mg/gCr) 11.0 (1.0–6407.4) 13.1 (1.1–3410.8)
ALT (IU/L) 22.5 ± 12.5 23.4 ± 14.9
TC (mg/dL) 175.4 ± 31.6 179.9 ± 32.1
TG (mg/dL) 132.2 ± 82.6 133.1 ± 79.4
HDL (mg/dL) 55.3 ± 16.6 57.1 ± 16.7
UA (mg/dL) 5.3 ± 1.7 5.1 ± 1.4
Baseline and 2-year after characteristics of the U-CARE study (n= 362 DKD patients). Mean ±
SD was for parametric factors and the median range was for nonparametric factors (eGFR, ACR,
PS, and suPAR). In the U-CARE study, eGFR (CKD-EPI) is the estimated eGFR based on the
equation of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). PS phenyl sulfate
concentration, suPAR soluble urokinase-type plasminogen activator receptor, duration duration
of diabetic mellitus, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, BS blood glucose level, HbA1c NGSP value, eGFR estimated glomerular filtration rate
(CKD-EPI), ACR urinary albumin-to-creatinine ratio, ALT alanine aminotransferase, TC total
cholesterol, TG triglyceride, HDL high-density lipoprotein cholesterol, UA uremic acid.
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concentration could predict the 2-year ACR deterioration in
DKD patients, especially with microalbuminuria.
Microbial enzymatic reduction of PS showed reno-protection.
Nonlethal inhibition of microbial-specific enzymes has a ther-
apeutic advantage, with lower selective pressure for the
development of drug resistance25. Phenol is synthesized from
dietary L-tyrosine by gut bacterial-specific tyrosine phenol-lyase
(TPL, EC 4.1.99.2)26 and absorbed phenol is metabolized in to PS
in the liver (Fig. 4a). TPL was reported to be expressed only in a
minor population of Enterobacteriaceae (e.g., Citrobacter, Proteus,
and Erwinia)26 and is not present in eukaryotes. Therefore, the
idea arose that TPL inhibition might decrease the plasma PS level
without any host toxicity. We synthesized the TPL inhibitors 2-
aza-tyrosine27 and L-meta-tyrosine28 was purchased. We then
examined their effects on the plasma PS level, albuminuria,
and renal function in a diabetic model. Oral administration of
Stage of diabetic nephropathy
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OR 95% CI p
Log(PS+1) 2.02 (1.04 3.92) 0.04
Log suPAR 0.97 (0.26 3.64) 0.96
age 0.98 (0.92 1.04) 0.43
Gender ( ref. male) 1.22 (0.37 4.06) 0.74
BMI 0.99 (0.86 1.13) 0.86
SBP 0.99 (0.96 1.03) 0.78
HbA1c 1.05 (0.53 2.05) 0.90
Log eGFR 0.19 (0.03 1.06) 0.06
1.0 2.0 3.0 4.0 5.00.0
False positive




























































r = 0.0955, p = 0.0696
y = –0.0698x+4.3514
r = 0.2162, p < 0.0001
y = 0.2698x+2.4197
r = 0.1674, p = 0.0003
95% confidence interval (CI)
a b c d
e
Fig. 3 The clinical significance of PS in DKD patients. a The relationship between the plasma PS concentration (n= 362). b The relationship between the
plasma PS concentration and the urinary albumin level (n= 362). c The relationship between the plasma PS concentration and the eGFR (n= 362). d The
relationship between the plasma PS concentration and soluble urokinase-type plasminogen activator receptor (suPAR) (n= 362). e PS is a predictor of 2-
year albuminuria. Adjusted odds ratio (95% confidence interval). Note that, among the known factors23, PS was the only factor that served as a predictor
of the progression of 2-year ACR in patients with microalbuminuria (n= 87). Receiver operating characteristic (ROC) curve analysis in the U-CARE Study,
showing comparison of known factors23. f AUC-ROC using known factors (0.713) and adjusted with PS (0.751) (n= 87). g AUC-ROC using known factors
(0.713) and adjusted with suPAR (0.725). (n= 87). h AUC-ROC using known factors with suPAR (0.725) and adjusted with PS (0.752) (n= 87)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09735-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1835 | https://doi.org/10.1038/s41467-019-09735-4 | www.nature.com/naturecommunications 7
2-aza-tyrosine (10 mg/kg/day) for 1 week significantly decreased
plasma PS, IS, and PCS in db/db mice (Fig. 4b). The increased
albuminuria observed during the progression of diabetes was
reduced by 2-aza-tyrosine (Fig. 4c, 10 mg/kg/day for 2 weeks).
Furthermore, it was clearly demonstrated that the plasma crea-
tinine (Cr) level was reduced by 2-aza-tyrosine (Fig. 4b), sug-
gesting a renoprotective effect. Similarly, another TPL inhibitor,
L-meta-tyrosine, also reduced the plasma PS and IS levels,
although the Cr level was not significantly changed in db/db mice
(Supplementary Fig. 9). These data suggested that 2-aza-tyrosine
reduced not only albuminuria, but also the PS and IS levels, with
a renoprotective effect in diabetic mice.
To confirm this renoprotective potency, we administered 2-
aza-tyrosine to a mouse model of adenine-induced renal failure29.
In this model, the plasma PS, IS, PCS, and TMAO levels were
significantly increased (Fig. 4d). By administering 2-aza-tyrosine
(5 mg/kg/day), the plasma Cr level was significantly decreased,
with plasma PS and IS levels showing a strong tendency to
decrease, but not statistically significant. Tissue PS and IS
contents are significantly increased in the renal cortex of kidney
failure mice shown by matrix-assisted laser desorption/ionization
(MALDI) mass spectrometry imaging (MSI)30. Imaging also
revealed that the tissue PS and IS levels were decreased by 2-aza-
tyrosine treatment (Fig. 4e). The quantitative tissue contents
analysis by LC/MS/MS clearly revealed that the PS, IS, PCS, and
TMAO levels were increased by renal failure and that the
accumulation of PS, IS, and TMAO were significantly reduced by
2-aza-tyrosine (Fig. 4f). Furthermore, the tubular area damaged
by renal failure was improved by 2-aza-tyrosine (Fig. 4g). It is
unclear how 2-aza-tyrosine reduced TMAO in renal failure tissue,
but the amelioration of renal failure by 2-aza-tyrosine may have,
in part, contributed to these beneficial phenomena.
Table 2 Multiple regression analysis (objective value: (PS+ 1))
Model 1 Model 2 Model 3
Regression
coefficient
95% CI p Regression
coefficient
95% CI p Regression
coefficient
95% CI p
Log ACRa 0.107 0.043 0.171 0.001 0.078 0.009 0.146 0.028 0.076 0.007 0.145 0.031
Agea 0.009 −0.0001 0.018 0.053 0.009 −0.0004 0.019 0.061
Gender −0.148 −0.333 0.038 0.119 −0.105 −0.303 0.092 0.297
BMI −0.010 −0.032 0.013 0.395 −0.009 −0.034 0.016 0.488
SBP −0.003 −0.009 0.003 0.337 −0.004 −0.011 0.004 0.345
HbA1ca −0.049 −0.138 0.040 0.280 −0.066 −0.159 0.026 0.161
Log eGFR −0.350 −0.758 0.058 0.093 −0.285 −0.720 0.149 0.199
Durationa 0.014 0.003 0.026 0.016
DBP 0.004 −0.008 0.015 0.520
ALTa 0.007 −0.001 0.015 0.105
TC 0.001 −0.002 0.005 0.503
TG −0.001 −0.002 0.001 0.432
HDL −0.001 −0.008 0.007 0.890
UA 0.028 −0.033 0.090 0.368
Multiple regression analysis based on clinical factors as an independent examined by variance inflation factor (VIF) <10. PS was used as an independent variable factor. Model 1 (crude model), model 2
(adjusted by known factors: age, gender, BMI, SBP, HbA1c, log (eGFR))23, and model 3 (full model, adjusted by model 2 plus fundamental clinical data in Supplementary Table 4 (DBP, ALT, TC, TG, HDL,
and UA) were used.
*p < 0.05 was regarded as statistically significant. Remaining variables after the stepwise method based on Akaike’s information criterion (AIC) in model 3 are depicted as *
Table 3 Multiple regression analysis (objective value: Log ACR)
Model 1 Model 2 Model 3
Regression
coefficient
95% CI p Regression
coefficient
95% CI p Regression
coefficient
95% CI p
Log(PS+ 1)* 0.270 0.108 0.431 0.001 0.176 0.020 0.332 0.028 0.176 0.017 0.335 0.031
Age −0.003 −0.017 0.011 0.652 −0.0004 −0.015 0.014 0.961
Gender* 0.333 0.056 0.611 0.019 0.396 0.097 0.695 0.010
BMI 0.020 −0.013 0.054 0.233 0.017 −0.022 0.055 0.397
SBP* 0.014 0.005 0.023 0.002 0.011 −0.0002 0.022 0.054
HbA1c 0.019 −0.115 0.152 0.786 0.035 −0.107 0.176 0.630
Log eGFR* −1.919 −2.502 −1.335 <0.001 −1.883 −2.516 −1.250 <0.001
Duration −0.003 −0.021 0.015 0.716
DBP* 0.010 −0.007 0.027 0.243
ALT −0.004 −0.016 0.009 0.579
TC −0.001 −0.006 0.005 0.761
TG 0.0004 −0.002 0.002 0.692
HDL 0.002 −0.010 0.013 0.795
UA 0.040 −0.054 0.134 0.403
Multiple regression analysis based on clinical factors as an independent examined by variance inflation factor (VIF) <10. ACR was used as an independent variable factor. Model 1 (crude model), model 2
(adjusted by known factors: age, gender, BMI, SBP, HbA1c, log (eGFR))23, and model 3 (full model, adjusted by model 2 plus fundamental clinical data in Supplementary Table 4 (DBP, ALT, TC, TG, HDL,
and UA) were used
*p < 0.05 was regarded as statistically significant. Remaining variables after the stepwise method based on Akaike’s information criterion (AIC) in model 3 are depicted as *
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The TPL-specific inhibitors 2-aza-tyrosine and L-meta-tyrosine
reduced not only plasma and tissue PS levels, but also IS levels in
the diabetic mouse model (Fig. 4b). PS is a metabolite of the
phenol that is generated by TPL (EC 4.1.99.2) using tyrosine as a
substrate. IS is generated by tryptophan indole lyase (TIL, EC
4.1.99.1) using tryptophan as a substrate31,32 (Fig. 4a). TPL and
TIL enzymes show high-sequence homology32. It is conceivable
that TPL inhibitors also partially inhibit TIL, resulting in a
simultaneous reduction in PS and IS concentrations. To clarify
this, we examined the effect of TPL inhibitors on TIL activity33.
The specific TIL inhibitor 2-amino-4-(benzimidazol-1-yl)butyric
acid (homo-BZI-Ala) at 100 μM, significantly inhibited TIL
(apotryptophanase) activity as reported33 (Fig. 4h). Concentra-
tions of 1 mM 2-aza-tyrosine and L-meta-tyrosine partly, though
significantly, inhibited TIL activity. These data suggest that 2-aza-
tyrosine inhibits both TPL and TIL, resulting in a dual reduction
in plasma PS and IS concentrations followed by the recovery of
renal damage.
2-Aza-tyrosine shows low-microbiota taxa pressure in RF mice.
To further investigate the effect of 2-aza-tyrosine on the gut
microbiota, we performed microbial 16S rRNA gene sequencing
of feces. The α-rarefaction (observed OTUs) (Fig. 5a), α-diversity
(Fig. 5b), and principal coordinates analyses using weighted
UniFrac analysis (Fig. 5c) revealed that 2-aza-tyrosine did not
cause a major shift in the major gut microbial composition. Next,
we focused on the microbiome in which the number positively
correlated with the plasma PS level in renal failure and was
reduced by 2-aza-tyrosine. At the order level, the major popula-
tion of gut microbiota (Bacteroidales, Clostridales, and Lactoba-
cillales) became more pronounced at >90% and did not follow the
criteria (Fig. 5d and Supplementary Fig. 10). However, two minor
populations of microbial order (Coriobacteria and Erysipelo-
trichales) showed a significant increase in renal failure, and these
increments were markedly decreased by 2-aza-tyrosine (Fig. 5e
and Supplementary Fig. 10). At the family level, Coriobacteriaceae
and Erysipelotrichaceae were significantly increased in renal fail-
ure and this rise was rescued by 2-aza-tyrosine (Fig. 5e and
Supplementary Figs. 11 and 12). At the genus level, the compo-
sition of the 12 major genera was not altered in renal failure mice
with or without 2-aza-tyrosine (Fig. 5e and Supplementary
Figs. 13–15). However, Adlercreutzia and unclassified Erysipelo-
trichaceae positively correlated with plasma PS concentration,
suggesting that these two minor taxa might, in part, influence the
change in the plasma PS level. TPL activity was found in the
Enterobacteriaceae family (Citrobacter, Proteus, and Erwinia)26,
but in this experiment, the relative abundance of Enterobacter-
iaceae was very small (less than 0.1%) and no correlation was
observed in the plasma PS concentration (Fig. 5e). We also found
that, after 1 week of cessation of L-m-tyrosine (10 mg/kg)
administration in db/db mice, the reduced plasma PS level
recovered (Supplementary Fig. 16). These data suggest that TPL
inhibitor did not significantly alter the major composition, but it
reduced the PS production with a minor taxon modification.
Taken together, these data suggest that PS is a marker and a
modifiable therapeutic target for DKD patients, especially those
with microalbuminuria, and TPL inhibitor did not significantly
alter the major composition, but it reduced the PS production
with a minor taxon modification (summarized in Fig. 6).
Discussion
It has been reported that the gut-derived metabolite PS is
markedly increased with the progression of renal failure34 and is
also higher in hemodialysis patients35. However, the precise
biological activity or toxicity has not been clarified. The cause of
DKD, includes irreversible (age, gender and duration of diabetes)
and modifiable (hyperglycemia, hypertension and albuminuria)
risk factors36. Intense multifactorial intervention targets glycemic
control, blood pressure, including renin–angiotensin system
blockade and dyslipidemia37. However, diabetic patients still have
a poorer outcome38. The main pathophysiological changes in
DKD kidney, include podocyte damage, thickening of the GBM,
interstitial fibrosis, and hyalinosis of blood vessels39, as well as
mitochondrial dysfunction in the podocytes16. We found that PS
was toxic in podocytes and also reduced mitochondrial function.
PS thickened the GBM and elicited inflammation with perivas-
cular fibrosis. These multitoxicities of PS on the DKD kidney
might lead to increased albuminuria. Therefore, DKD patients
with a high-PS level should reduce the PS level to prevent the
progression of albuminuria.
Although the limitations have been reported40, micro-
albuminuria is still a central target in the prevention and
Table 4 Logistic regression analysis
Model 1 Model 2 Model 3
Odds 95% CI p Odds 95% CI p Odds 95% CI p
Log(PS+ 1) 1.42 1.02 1.98 0.040 1.27 0.88 1.84 0.202 1.34 0.91 1.95 0.135
Log SuPAR 2.42 1.27 4.59 0.007 1.42 0.66 3.08 0.371 1.39 0.61 3.14 0.435
Age 0.99 0.95 1.02 0.447 0.98 0.94 1.02 0.294
gender (ref. male) 1.18 0.61 2.28 0.624 1.32 0.65 2.68 0.447
BMI 1.01 0.93 1.09 0.866 1.00 0.91 1.09 0.976
SBP* 1.01 0.99 1.04 0.262 1.03 1.00 1.06 0.026
HbA1c 0.93 0.65 1.33 0.704 0.99 0.68 1.43 0.950
log eGFR* 0.10 0.03 0.32 <0.001 0.12 0.03 0.46 0.002
duration 0.99 0.95 1.04 0.729
DBP* 0.96 0.93 1.00 0.071
ALT 1.00 0.97 1.03 0.970
TC* 0.99 0.97 1.00 0.093
TG 1.00 1.00 1.01 0.279
HDL* 1.03 1.00 1.06 0.049
UA* 1.22 1.02 1.45 0.026
Two-year ACR deterioration shown by logistic regression analysis based on whole DKD. Model 1: only log(PS+ 1) and Log suPAR (crude model), Model 2: Model 1 with known factors (age, gender, BMI,
SBP, HbA1c and log eGFR)23, Model 3: Model 2 with other factors (duration, DBP, ALT, TC (total cholesterol), TG (triglyceride), HDL (high-density lipoprotein), and UA (uric acid)). The 95% confidence
interval (95% CI) is listed
Remaining variables after the stepwise method based on the Akaike’s information criterion (AIC) in model 3 are depicted as *
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treatment of DKD37, and identifying which patients with
microalbuminuria are most likely to develop more advanced
kidney disease is important. We found that PS is related to
the basal ACR and to the progression of albuminuria, sug-
gesting the effectiveness of measuring PS in DKD patients
with microalbuminuria. In addition, reducing circulating
PS levels might also reduce the risk of DKD development
(Fig. 6).
The circulating concentrations of uremic toxins is dependent






































































































































































































































































































































ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09735-4
10 NATURE COMMUNICATIONS |         (2019) 10:1835 | https://doi.org/10.1038/s41467-019-09735-4 | www.nature.com/naturecommunications
dietary effect of tyrosine on the PS concentration, we measured
the PS levels in plasma collected serially over time in control
(C57BL6) and diabetic (db/db) mice. After oral tyrosine admin-
istration, a greater increase in plasma PS level in diabetic mice
occurred during the 4-h study period and peaked at 2 h compared
with that of control (Supplementary Fig. 17). In addition, the
serum PS level was higher in diabetic mice. The restriction of
dietary protein is recommended for reducing glomerular hyper-
filtration and pro-inflammatory gene expression in both CKD
and DKD patients42. Our data suggests another aspect that
reducing tyrosine intake in diabetic patients might decrease PS
production, thereby reducing albuminuria and being
renoprotective.
Concerning eGFR, our analysis uses only two time points of
eGFR and the median eGFR decline was −1.8 in 2 years. Since the
change in eGFR was small, we will need another cohort with a
long observation period to reach a clear conclusion on the rela-
tion between PS and eGFR. In addition, under the absent decline
in GFR, there is no role for circulating factor suPAR. The dif-
ference in the sensitivity between PS and suPAR may not be an
issue with suPAR but rather with the cohort.
2-Aza-tyrosine reduced both PS and IS in the diabetic model. It
is well-known that the charcoal adsorbent AST-120 significantly
reduces PS and IS35. IS accelerates the progression of CKD43, but
the contribution on albuminuria was limited43. Administration of
IS to renal failure rats declined renal function, but the proteinuria
was not changed43 In diabetic patients with normal renal func-
tion, AST-120 reduced the progression of renal dysfunction
without changing IS level44. 2-Aza tyrosine decreased both PS
and IS, the contribution of PS to albuminuria in db/db mice
might be more potent than IS.
Our data showed that proteinuria was rapidly reduced in PS-
loaded animals and we found that PS has a podocyte
mitochondrial toxicity. It was reported that podocyte-specific loss
of PHB2, a mitochondrial inner membrane structural protein led
to early onset of proteinuria in 3-weeks and death after 5 weeks45.
On the other hand, in our previous experiment, mitochondrial
DNA knockout mice generate renal damage after 7–9 months46.
The difference in onset may be attributed to differences in the
model. We found that the combination PS and suPAR
improved the c-statistics and this phenomenon raised another
possibility of another mechanism of podocyte injury, e.g., suPAR
is binding to and activating αv α3 integrins on podocytes, a
process that leads to activation of small GTPase Rac-1 which in
turns drives podocyte foot process motility and foot process
effacement47.
The interference of gut microbiota may involve in the patho-
genesis or development of diabetes48 and CKD49. However, little
is known regarding DKD. It was reported a significant disruption
of the epithelial tight junction in different CKD models50. In
HFD-induced obesity and diabetes mice, expression of the tight
junction proteins zonula occludens-1 (ZO-1) and occludin
decreased51. We examined the epithelial tight junction in WT and
transgenic rats and the expression levels of claudin I, occludin,
and ZO-1 in the ileum and colon were unchanged (Supplemen-
tary Fig. 18).
We found that the microbial orders Coriobacteria and Erysi-
pelotrichales increased in renal failure and decreased by 2-aza-
tyrosine. Coriobacteriaceae are gram-positive anaerobic bacteria
and in our previous study, the Coriobacteriaceae family and
Adlercreutzia were increased in renal failure mouse, but our
intervention did not alter the increase52. It was reported that in
CKD patients, the low-GFR group showed increased Adler-
creutzia, which positively correlated with the TMAO level53.
Erysipelotrichale are also gram-positive anaerobic bacteria and
some types have been isolated from human feces and the bacteria
encodes TPL54. Erysipelotrichales showed a decrease in Crohn
disease patients55, but little has been clarified the relation to renal
disease.
TPL has been found in a number of different strains of bac-
teria, most of which belong to the Enterobacteriaceae family,
specifically to the genera Citrobacter, Proteus, and Erwinia26.
However, the Enterobacteriales family and the Enterobacteriaceae
family represent a minor population and little is known about the
pathogenic contribution of such gut microbiota to human dis-
eases. We also found that the microbial genus Adlercreutzia and
Erysipelotrichaceae unclassified significantly correlated with a
change in the PS levels. However, the TPL gene was not reported
in the taxa according to the Genbank database search. Further
experiments are needed to clarify the microbiome that produces
phenol in renal failure.
The production of phenols and indoles by gut bacteria is
associated with a variety of diseases in humans and animals.
Phenols have been implicated as having a possible role in
the causation of large bowel cancer56 and as causal factors in
leukemia57. Elevated plasma levels of the phenol derivative
4-ethylphenylsulfate may promote anxiety-like behavior58. Che-
mical inhibition of TPL may also have a beneficial effect in pre-
venting the phenol-induced disorders.
In conclusion, PS is not only an early diagnosis marker,
but also a modifiable cause and therefore a target for
the treatment of DKD. Chemical reduction of microbiota
Fig. 4 TPL inhibitors lowered PS concentrations and reduced renal damage in mouse models of diabetic kidney disease and adenine-induced renal failure.
a Scheme of gut microbiome-derived PS, PCS, and IS generation. Dietary tyrosine is converted to phenol by tyrosine phenol-lyase (TPL) and further
modified to produce PS or PCS. Dietary tryptophan is first converted to indole by tryptophan indole-lyase (TIL), further converted and finally modified into
IS. Specific inhibitors of TPL are 2-aza-tyrosine and L-meta-tyrosine, while homo-BZI-Ala is a specific inhibitor of TIL. b Plasma concentrations of PS, IS,
PCS, TMAO, and Cr in db/db mice before (Pre) and after treated with 2-aza-tyrosine (post, 10mg/kg, n= 10). c Urinary albumin/creatinine ratio of db/db
mice with either no intervention (Ctrl) or treatment with the TPL inhibitor 2-aza-tyrosine (AZA). N= 6 in each group. d Plasma concentrations of PS, IS,
PCS, TMAO, and Cr in the adenine-induced renal failure mouse model treated with 2-aza-tyrosine (5 mg/kg) for 14 days. Four groups were measured:
control mice (Ctrl), control mice treated with 2-aza-tyrosine (AZA), adenine-induced renal failure mice with no intervention (RF), and adenine-induced
renal failure mice treated with 2-aza-tyrosine (RF-AZA). n= 5 in each group. e Representative imaging mass spectrometry spectra of PS and IS in kidney
sections from renal failure mice (RF) and renal failure mice administered 2-aza-tyrosine (5 mg/kg) (RF+AZA). Mass spectrometry imaging shows the
distribution of PS ([M-H]−, m/z 172) and IS ([M-H]−, m/z 212). Scale bar, 1000 μm. f Quantitative analysis of PS and IS tissue contents in mouse kidneys
in RF (n= 4) and others (n= 5). g Morphometric analysis of the fractional cortical tubular area of Masson trichrome stained whole kidney images. n= 5 in
each group. Data are presented as the percentage of the total cortex (n= 5). Scale bar, 500 μm. h Enzymatic activity of TIL. TIL activity under control
conditions (Ctrl), with TIL inhibitor homo-BZI-Ala (100 μM) and a tyrosine phenol-lyase inhibitors (L-meta-tyrosine (LmT) or 2-aza-tyrosine (AZA),
1 mM), n= 3. *p < 0.05 vs. control according to Paired t test (b), data are mean ± SEM *p < 0.05 vs. control according to t test (c, d, g, f) or Tukey–Kramer
test (h, *p < 0.05, **p < 0.01, ***p < 0.001). Source data are provided as a Source Data file
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TPL should represent another aspect for developing drugs
preventing DKD.
Methods
Materials. PS and 13C6 labeled PS were synthesized by Sundia MediTech
(Shanghai, China) and ISOTEC (Sigma-Aldrich), respectively. 2-Aza-tyrosione27
and 2-amino-4-(benzimidazol-1-yl)butyric acid (Homo-BZI-Ala)33 were
chemically synthesized. L-meta-tyrosine was purchased from Astatech (Bristol,
PA). HUPEC13 were provided by Dr. Jeffrey B. Kopp (NIH, Bethesda). Human
kidney proximal tubule cell line HK-2 (CRL2190) and Canine kidney cell line
MDCKII (CRL2936) were purchased from ATCC.
Animal experiments. The animal protocols were approved by the Tohoku Uni-
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This study was conducted in accordance with the Guide for the Care and Use of
Laboratory. SLCO4C1-Tg rats6 were bred at Tohoku University. C57BL6 mice, db/
db mice and KKAy mice were obtained from CLEA Japan (Tokyo, Japan). Diabetes
was induced in 8-week-old SLCO4C1-Tg rats6 by an intraperitoneal injection of
STZ (50 mg/kg) dissolved in a 0.1 M citrate–phosphate buffer (pH 4.2)59. We
estimated drug intake (PS, 50 mg/kg/day; 2-aza, 5 mg/kg/day; and L-meta-tyrosine,
10 mg/kg/day) by measuring the amount of water intake. For the renal failure
model, 8-week-old C57BL/6N Jcl mice were fed a diet containing 0.2% wt/wt
adenine for 6 weeks to induce tubular injury29, each group was further divided and
2-aza-tyrosine (10 mg/kg) was orally administrated for 2 weeks with normal chow.
The urinary protein level was determined by enzyme-linked immunosorbent assay
(ELISA) (Nephrat II, Exocell Inc., Philadelphia, PA). Plasma was collected from the
experimental rats and the glucose, insulin, creatinine and BUN concentrations were
measured according to the kit instructions (Wako Pure Chemical, Osaka, Japan).
Histological examination. Kidney was fixed in 10% neutral buffered formalin and
embedded in paraffin. Kidney sections were stained with periodic acid-Schiff
(PAS), Masson’s trichrome, and Sirius red. For morphometric analysis of the
glomeruli, PAS-stained sections were used for histomorphometric analysis. The
whole-glomerular tuft volume was measured according to the reported method60.
The area was quantified by measurement at ×200 magnification in 50 random
nonoverlapping fields in each group (n= 4) using Image J (Figs. 1b and 2c). In
SLCO4C1 TG rats, the preserved tubular area and fibrotic area (Sirius Red positive
area) were quantified by measurement at ×20 magnification in whole renal cortex
area in the field using Image J software (NIH, Bethesda, MD). In mice, the glo-
merular sclerosis area was measured using PAS-stained sections by Image J soft-
ware, as reported19. In each analysis, 50 sections were examined from 3 animals in
each examination. The preserved tubular area was also quantified by measurement
at ×20 magnification in the whole renal cortex area in the field using Image J. The
fibrotic area was quantified by measurement at ×200 magnification in 20 random
nonoverlapping fields using Image J61. Electron microscopic analysis was per-
formed as previously reported17. The mesangial matrix score was determined in at
least 450 glomeruli from a total of 10 mice. Two pathologists, blind to the treat-
ment of the individual rats or mice, performed the evaluation.
Untargeted metabolomics. Plasma samples were taken from STZ-treated wild
type rats: d7 (n= 6), d63 (n= 3), and d119 (n= 3). Plasma samples were also
taken from STZ-treated transgenic rats: d63 (n= 3) and d119 (n= 4). Plasma
samples were deproteinized by adding equal volumes of acetonitrile, then vortexed
and centrifuged at 15,000×g for 5 min at room temperature and the supernatants
were analyzed. UHPLC-QTOF/MS analysis was performed on an Acquit Ultra
Performance LC I-class system (Waters Corp. Milford, MA) connected to a Waters
Synapt G2-Si QTOF MS fitted with an electrospray ionization (ESI) source oper-
ated in the negative ion mode. Samples were separated using a Waters Acquity
UPLC BEH Amide Column (1.7 μm, 2.1 × 150 mm) kept at 45 °C and a flow rate of
0.4 mL/min. Acetonitrile (10 mM ammonium bicarbonate (95:5, v/v) was used as
mobile phase A and acetonitrile (10 mM ammonium bicarbonate (5:95, v/v) was
used as mobile phase B. The gradient was applied as follows: 1% B at 0–0.1 min,
Fig. 5 Effect of 2-aza-tyrosine (AZA) on the gut microbiome in adenine-induced renal failure mice. a Observed OTUs rarefaction analysis. OTU rarefaction
curves of gut microbiome were used to estimate richness in the following groups: control mice (Ctrl); control mice treated with 5mg/kg 2-aza-tyrosine
(AZA); adenine-induced renal failure mice (RF); and adenine-induced renal failure mice treated with 5mg/kg 2-aza-tyrosine (RF-AZA). b OTU-based α-
diversity of each microbiome. No significant diversity was seen in any group by Chao1 (left) and Shannon (right) analyses. c Principal coordinates analysis
of the microbiome profiles using weighted UniFrac. Scores are presented for the first principal component (PCo1) vs. both the second principal component
(PCo2) and the third principal component (PCo3). d Relative abundance of microbiota based on the average number of each subgroup at order, family and
genus levels. The major subgroups are indicated on the right. e The relative abundance of microbiota differed significantly among the four groups analyzed.
The y-axis indicates the relative abundance of each microbe as a percentage. The proportional change in the minor groups correlated with renal failure and
2-aza-tyrosine treatment. The major microbial order (Bacteroidales, Clostridales, and Lactobacillales) were unchanged by either renal failure or 2-aza-
tyrosine treatment. However, the minor populations (Coriobacteriales and Erysipelotrichales) were significantly changed in the correlation with the PS
concentration by renal failure and 2-aza-tyrosine treatment. n= 5 in each group. Data were mean ± SEM. Statistical analysis was performed by the
Tukey–Kramer test, followed by FDR correction of p values. *pFDR < 0.1 was treated as statistically significant. The following groups were tested: control
group (Ctrl); control group administered 2-aza-tyrosine (AZA); the renal failure group (RF); and the renal failure group administered 2-aza-tyrosine (RF-



































Fig. 6 A schematic model of the generation and toxicity of PS. In gut microbiota, TPL converts tyrosine to phenol and ammonia. PS is also generated in the
liver. PS accumulates in plasma as a metabolite and has deleterious effects on the vasculature and kidneys. In diabetic kidney disease, PS damages
podocytes, accelerates GBM thickening, and induces proteinuria. Treatment with TPL inhibitors reduces plasma PS levels and prevents the progression of
renal failure in animal models
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1–70% B at 0.1–6.0 min, 70–1.0% B at 6.0–6.5 min, and 1% B at 6.5–10.0 min. All
data were processed using ProgenesisQI software (Nonlinear Dynamics, Newcastle,
UK) for peak picking, alignment, and normalization to produce peak intensities for
retention time (tR) and m/z data pairs. Features were identified from the Chem-
spider DB, Human Metabolome Database (HMDB) and Lipidmaps using the
precursor and fragment ion spectra obtained by MS. The intensities of the iden-
tified features were imported to EZinfo software (Waters) for multivariate analysis,
and their relative quantities were evaluated by PCA, PLS-DA, and OPLS-DA.
Quantification of PS, PCS, IS, and TMAO by LC/MS/MS methods. PS, PCS, IS,
and TMAO levels in animal plasma were measured as we recently reported8.
Briefly, deuterated internal standards were used for all analytes and a TSQ
Quantum Ultra triple quadrupole mass spectrometer (Thermo Fisher Scientific,
Waltham, MA) equipped with a heated ESI source system was used. The mass
spectrometer was operated in both positive and negative ionization modes. Samples
were analyzed in single reaction monitoring mode by monitoring the ion transi-
tions: m/z 173.0–>93.3 for PS. Data were acquired and analyzed using Xcalibur™
software (version 2.1, Thermo Scientific). For the human samples, the PS level in
fresh-frozen plasma was measured by another method to help clinicians measuring
PS by LSI Medience Co. (Tokyo, Japan). Briefly, LC–MS/MS data sets were
acquired with a liquid chromatograph Nexera X2 LC0AD equipped with an ESI
and triple quadrupole mass spectrometer 8050 (Shimadzu, Japan). The mass
spectrometer was operated in the negative mode. The main parameters of the mass
spectrometer are summarized in Supplementary Fig. 19. Data acquisition and
analysis were performed using Shimadzu Lab Solutions version 5.89. The corre-
lation of each measurement was confirmed with the correlation >0.99269 (Sup-
plementary Fig. 19). The plasma levels of suPAR were measured by ELISA using
the Quantikine Human suPAR Immunoassay kit (R&D Systems, Minneapolis,
MN) according to the manufacturer’s instructions.
Uptake experiment. Madin-Darby Canine Kidney (MDCK) II cells were stably
transduced with SLCO4C1 or an empty vector and uptake experiments were
performed as previously reported9. Uptake in HK-2 cells was initiated by adding
50 μM PS in the absence or presence of 100 μM ritonavir, a SLCO4C1 inhibitor.
Uptake was terminated after a 10 min incubation. The concentration of PS in the
cells was measured using LC/MS/MS. The uptake was calculated by dividing the
uptake amount by the protein content of the cells.
Cell toxicity assay. Differentiated HUPEC13 were cultured in
RPMI1640 supplemented with 2% FBS and plated at 0.5 × 104 cells/0.5 mL assay
medium per well in 96-well collagen-coated culture plates and modified with the
relevant culture condition, as reported14. After each compound was applied at the
final concentration indicated, differentiated podocytes were cultured for 72 h and
cell viability was measured by Cell Count Regent SF (Nacalai Tesque, Kyoto, Japan)
as previously reported17. To measure the glutathione levels, a CellTiter-
GloLuminescent Cell Viability Assay kit and a GSH/GSSG-Glo™ Assay kit were
used (Promega, Madison, WI).
Mitochondrial function measurement. Bioenergetic analysis of human cultured
podocytes was carried out as previously described17. Briefly, the OCR and pH
gradient (ECAR) of the fibroblasts from the Leigh patients or normal volunteers
were measured using Seahorse XF 24 (Seahorse Bioscience). Cells were cultured in
assay medium (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mMmgCl2,
2 mM HEPES, 1.0 mM EGTA and 0.2% (w/v) fatty acid-free bovine serum albumin
(BSA), pH 7.2) without CO2 for 60 min. After equilibration, cells were measured in
the three respiration states followed by injections of three inhibitors of oxidative
phosphorylation.
Recruitment and measurement of the U-CARE cohort study. The Urinary
biomarker for continuous and rapid progression of diabetic nephropathy (U-
CARE) study20 is a multicenter, observatory clinical study that planned to inves-
tigate the urinary biomarkers in diabetic nephropathy (UMIN 00011525).
For diabetic nephropathy patient cohort study, we recruited 362 patients (U-
CARE, registered UMIN 00011525). The analysis was approved by both the
Tohoku University Ethics committee (2017-1-870) and Okayama University Ethics
committee (1702-026). The collection of human samples was performed in
accordance to the Tohoku University (2017-1-870) and after obtaining written
informed consent adopted by the Okayama University (UMIN 00011525 and 1702-
026). The study design and baseline characteristics were as follows: eligible
participants were between 20 and 80 years of age with type 1 and type 2 diabetes
and excluded people with liver cirrhosis and a new onset of malignancies within
5 years. Among 777 patients enrolled in 2012, 564 participants were eligible for
enrollment in this study. An included criterion was that serum samples stocked in
2014 and clinical data between 2014 and 2016 would be available. Among the 564
participants, 362 patients with full data were selected. The phlebotomy protocol
was as follows. Although blood at random visits could clot at room temperature for
between 30 min and 2 h, samples were centrifuged, frozen at −80 °C and shipped
on dry ice to the Okayama University Hospital, where the samples were aliquoted
and frozen at −80 °C. Laboratory processing was performed at each enrolled
hospital. Estimated GFR (eGFR) was calculated according to gender, age and the
concentration of serum Cr according the Japanese equation Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI)62. CKD-EPI is multiplied by
a Japanese coefficient of 0.813; eGFR= 0.813 × 141 × min(SCr/κ, 1) α max
(SCr/κ, 1)−1.209 × 0.993Age × 1.018 [if female]α, where SCr is serum creatinine, κ is
0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min
indicates the minimum of SCr/ or 1, and max indicates the maximum of SCr/ or 1.
Several baseline variables were measured as confounding factors. For BMI, some
participants did not have information on BMI at baseline. To keep the sample size,
we imputed an average of BMI measured 1 year before baseline and 1 year after
baseline.
Statistical analysis of clinical data in DKD patients. Parametric factors are
presented as means and standard deviations or as medians and interquartile ranges.
Nonparametric factors are presented as proportions by the result of Shapiro–Wilk
test. As a result, skewed variables (eGFR, ACR, PS, and suPAR) were logarith-
mically transformed to improve normality prior to analysis. Since some PS values
in the U-CARE study were calculated as 0 according to the measurement limit, we
added 1 to calculate log transformed values. The correlation between the plasma PS
level and various factors was calculated using the Spearman rank-order correlation.
To perform multiple regression analysis, we built 3 models as an independent
variable examined by variance inflation factor (VIF) <10, and the plasma PS level
and ACR were used as objective variables. Model 1 is the crude model. Model 2 is
adjusted by known factors: age, gender, BMI, SBP, HbA1c, and log (eGFR))23.
Model 3 is the full model, adjusted by model 2 plus other clinical factors in
Supplementary Table 4 (DBP, ALT, TC, TG, HDL, and UA). Since blood sampling
did not involve fasting and was strongly related to HbA1c, we did not adjust serum
glucose concentration in the following analyses. A logistic regression analysis was
also used to identify the factors independently associated with the development of
2-year ACR deterioration. We defined the increased ACR cases as follows63,64:
normoalbuminuric at baseline: a case that progressed from normoalbuminuria to
microalbuminuria or macroalbuminuria. Microalbuminuric at baseline: a case that
progressed from microalbuminuria to macroalbuminuria or a case with ACR that
doubled or more. Macroalbuminuric at baseline: a case with ACR that doubled or
more. To identify the factors independently associated with the development of 2-
year ACR, the same 3 multiple logistic regression models were used. Model 1: only
log(PS+ 1) and log(SuPAR) (crude model). Model 2: Model 1 with known factors
(age, gender, BMI, SBP, HbA1c, and log(eGFR))23. Model 3: Model 2 with other
factors (duration, DBP, ALT, TC, TG, HDL, and UA). Results are presented as
odds ratios (ORs) with 95% CIs. ORs for all continuous variables were computed
for each standard deviation (SD) change. *p < 0.05 was set as statistically significant.
The stepwise method was also performed based on the Akaike's information
criterion (AIC).
Microbiome analysis. The genomic DNA of gut microbiota was extracted from
murine feces. The 16S rRNA genes in the DNA samples were analyzed using a
MiSeq sequencer (Illumina, San Diego, CA)29. Microbial genomic DNA was
extracted using a phenol–chloroform standard protocol, with vigorous shaking
with 0.1 mm zirconia/silica beads. The V1–V2 region of the 16S rRNA genes was
amplified from the extracted DNA using the bacterial universal primer set Rd1 SP
sequence-27Fmod (5′-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-A
GRGTTTGATYMTGGCTCAG-3′) and Rd2 SP sequence-338R (5′-GTGACTGG
AGTTCAGACGTGTGCTCTTCCGATCT-TGCTGCCTCCCGTAGGAGT-3′)65.
Polymerase chain reaction (PCR) was performed with Tks Gflex DNA Polymerase
(Takara Bio Inc.) and amplification proceeded with one denaturation step at 94 °C
for 1 min, followed by 20 cycles of 98 °C for 10 s, 55 °C for 15 s and 68 °C for 30 s,
with a final extension step at 68 °C for 3 min. The PCR products were purified
using Agencourt AMPure XP (Beckman Coulter Inc.) and further amplified using a
forward primer (5′-AATGATACGGCGACCACCGAGATCTACAC-NNNNNNN
N-ACACTCTTTCCCTACACGACGC-3′) containing the P5 sequence, a unique 8
bp barcode sequence for each sample (indicated in N), and Rd1 SP sequence and a
reverse primer (5′-CAAGCAGAAGACGGCATACGAGAT-NNNNNNN
N-GTGACTGGAGTTCAGACGTGTG-3′) containing the P7 sequence, a unique
8-bp barcode sequence for each sample (depicted as N), and Rd2 SP sequence.
After purification using Agencourt AMPure XP (Beckman-Courter), mixed sam-
ples were prepared by pooling approximately equal amounts of PCR amplicons
from each sample29. Finally, MiSeq sequencing was performed according to the
manufacturer's instructions. In this study, 2 × 300 bp paired-end sequencing was
employed. As a result, 687,826 paired-end reads were obtained. To assemble the
reads, fast length adjustment of short reads (v1.2.11)66 was used. 615,077 paired-
end reads were assembled. Assembled reads with an average Q value <25 were
filtered out using in-house script. The number of reads per sample was from 27,828
to 35,423. From each sample, 27,828 filter-passed reads were randomly selected and
used for further analysis. Reads were then processed using quantitative insights into
microbial ecology (QIIME) (v1.9.1) pipeline67. Sequences were clustered into
operational taxonomic units (OTUs) using 97% sequence similarity and OTUs
were assigned to taxonomy using the uclust method.
In microbiome analysis, PFDR was calculated using the Benjamini and Hochberg
false-discovery rate method (α = 0.05) to adjust for independent multiple
comparisons68. FDR calculation used the p.adjust function of the stats package of
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the R statistical language, version 3.4.2 (http://www.r-project.org/)69. *PFDR < 0.1
was treated as statistically significant. JMP Pro software version 12 (SAS Institute
Inc., Cary, NC) was used for statistical analysis.
TIL (apotryptophanase) activity measurement. The assay was carried out in a
cuvette (1 cm optical path length) in a BioSpectrometer Kinetic (Eppendorf,
Hauppauge, NY) at 37 °C as previously reported70, but with some modification.
The reaction mixture contained 0.005% BSA (Sigma), 1 mM reduced glutathione
(Sigma), 100 μM pyridoxal phosphate (Sigma), 100 μM NADH (Sigma), 3 U/mL
lactate dehydrogenase (Sigma) and apotryptophanase (10 U/mL, Sigma) in
0.15M potassium phosphate buffer (pH 8.0). Following a 3 min incubation with
inhibitor, the enzymatic reaction was initiated by adding L-tryptophan (300 μM
final, Sigma). The decrease in optical density at 340 nm was monitored for 5 min
at 5 s intervals and used for calculating the TIL reaction velocity. The inhibitory
effect of TPL inhibitors (2-aza-tyrosine and L-meta-tyrosine) on TIL enzymatic
activity was measured. Homo-BZI-Ala was used as a positive control of TIL
inhibitor.
Mass spectrometry imaging of kidney sections. MSI of kidney sections was
performed as previously reported30. Briefly, kidney tissues were sectioned to 8 μm in
thickness with a cryostat and thaw-mounted onto indium tin oxide-coated glass
slides. Using a 0.3 mm caliber nozzle airbrush (Procon boy FWA Platinum; Mr.
Hobby), 9-AA (750 μL, 4.5mg/mL in methanol) was sprayed on the slide. MALDI-
MSI analysis was performed using iMScope (Shimadzu, Japan). Mass spectra of the
designated areas on a specimen photographed before matrix application were
acquired in the negative ion mode. Mass spectra were acquired under the condition of
a laser frequency and scanning mass ranging fromm/z 200 tom/z 220 andm/z 170 to
m/z 189. The spatial interval of data points was 50 μm, giving 10,120 data points in
total for each section. The data collected through the microscopic system were
digitally processed using Imaging MS Solution analysis software (Shimadzu).
Quantitative PCR analysis. Whole kidneys were homogenized in TRIzol reagent
(Invitrogen) and extracted according to the manufacturer’s directions. The cDNA
synthesis was performed using a transcri ptor first strand cDNA synthesis kit
(Roche). Primers purchased from Applied Biosystems are shown in Supplementary
Table 10. The sequences of the primers and probes are certificated by the company,
but not open based on the company policy.
Western blot. Western blotting of ileum and colon were performed as previously
described61. The primary antibodies against claudin 1 (1:1000 dilution, ab15098),
occludin (1:1000 dilution, ab31721), and ZO-1 (1:1000 dilution, abG041) were
purchased from Abcam.
Statistical analysis. The data are expressed as means ± SEM or SD. *p < 0.05,
**p < 0.01, and ***p < 0.001 were considered statistically significant. JMP Pro
software version 12 (SAS Institute., Cary, NC) was used for the statistical analyses.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. The source data underlying Figs. 1a, b, 1g, 1j, 2a, b,
2d–g, 2i, j, 4b–d, 4f–h, 5a–e, and Supplementary Figs. 1, 3–7, 9, 16–19, Supplementary
Tables 2 and 3 are provided as a Source Data file. Untargeted metabolome analysis
underlying Fig. 1c–f, Supplementary Fig. 2a–d and Supplementary Table 1 are provided
in a file named Supplementary Data 1. The microbiome data were deposited in the DDBJ
database (https://trace.ddbj.nig.ac.jp/DRASearch/) under accession number DRA006253.
A Reporting Summary for this Article is available as a Supplementary Information file.
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